Long Acting GnRH Antagonist in PCOS Women Undergoing IVF
Status:
Unknown status
Trial end date:
2015-02-01
Target enrollment:
Participant gender:
Summary
PCOS is a common endocrinopathy affecting 5-10% of women in their reproductive age
characterized by hyperandrogenism, chronic anovulation and polycystic ovaries. This syndrome
is a serious problem in IVF since there is a high risk of developing ovarian hyperstimulation
syndrome (OHSS) during ovarian stimulation with gonadotropins. The introduction of GnRH
antagonist in IVF has reduced the incidence of severe OHSS, still maintaining a good ovarian
response and pregnancy rate. Recently, a long acting GnRH antagonist, Degarelix, was
introduced for prostatic cancer treatment. Furthermore a recent paper reported its use also
for the induction of multiple follicular growth in a program of oocyte donation. The aim of
this study is to evaluate the feasibility of GnRH antagonist depot use in a protocol of
controlled ovarian hyperstimulation in PCOS women at risk of developing OHSS in IVF cycles.